PharmEasy, a Mumbai-based healthcare startup is reported to close its $100 Million Series D funding round next week. The company’s existing investors took a part in this round along with a new Korean venture capital firm. While the company has already signed the term sheet, it is likely to close the deal sometime next week. PharmEasy will use these funds towards the company’s expansion, research, and development. The Series D round will raise PharmEasy’s total funding to $208.5 million. Reportedly, PharmEasy, in its Series C round, had secured $50 million from its investors in September 2018. The company currently has eight existing investors – Eight Roads Ventures India (the proprietary investment arm of Fidelity International Ltd.), F-Prime Capital, Fundamentum Advisors (an investment firm backed by Nandan Nilekani and Sanjeev Aggarwal), Avendus Capital and San Francisco-based hedge fund Think Investments among a few others. The company operates on a full-stack model where it procures the medicines directly from the manufacturers and delivers them to the customers.